KR101158968B1 - 친수성/친유성 중합체 매트릭스 용량적 제제 - Google Patents

친수성/친유성 중합체 매트릭스 용량적 제제 Download PDF

Info

Publication number
KR101158968B1
KR101158968B1 KR1020097017509A KR20097017509A KR101158968B1 KR 101158968 B1 KR101158968 B1 KR 101158968B1 KR 1020097017509 A KR1020097017509 A KR 1020097017509A KR 20097017509 A KR20097017509 A KR 20097017509A KR 101158968 B1 KR101158968 B1 KR 101158968B1
Authority
KR
South Korea
Prior art keywords
layer
active
weight
tablet
active layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020097017509A
Other languages
English (en)
Korean (ko)
Other versions
KR20090094406A (ko
Inventor
귀 베르그놀
파스칼 그르니에르
로레타 매기
우발도 콘테
Original Assignee
자고텍 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26332740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101158968(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT2000MI000852A external-priority patent/IT1318470B1/it
Priority claimed from IT2000MI001963A external-priority patent/IT1318687B1/it
Application filed by 자고텍 아게 filed Critical 자고텍 아게
Publication of KR20090094406A publication Critical patent/KR20090094406A/ko
Application granted granted Critical
Publication of KR101158968B1 publication Critical patent/KR101158968B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097017509A 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제 Expired - Lifetime KR101158968B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT2000MI000852A IT1318470B1 (it) 2000-04-14 2000-04-14 Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologiamente attive a velocita' predeterminata.
ITMI2000A000852 2000-04-14
IT2000MI001963A IT1318687B1 (it) 2000-09-07 2000-09-07 Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologicamente attive a velocita' predeterminata.
ITMI2000A001963 2000-09-07
PCT/GB2001/001726 WO2001078688A1 (en) 2000-04-14 2001-04-12 Hydrophilic/lipophilic polymeric matrix dosage formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011476A Division KR20080047630A (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제

Publications (2)

Publication Number Publication Date
KR20090094406A KR20090094406A (ko) 2009-09-04
KR101158968B1 true KR101158968B1 (ko) 2012-06-21

Family

ID=26332740

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020097017509A Expired - Lifetime KR101158968B1 (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제
KR1020077013182A Ceased KR20070065922A (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제
KR1020087011476A Ceased KR20080047630A (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제
KR1020027013768A Expired - Lifetime KR100823392B1 (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020077013182A Ceased KR20070065922A (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제
KR1020087011476A Ceased KR20080047630A (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제
KR1020027013768A Expired - Lifetime KR100823392B1 (ko) 2000-04-14 2001-04-12 친수성/친유성 중합체 매트릭스 용량적 제제

Country Status (23)

Country Link
US (4) US20030180359A1 (enExample)
EP (4) EP1272167B1 (enExample)
JP (2) JP5073907B2 (enExample)
KR (4) KR101158968B1 (enExample)
CN (1) CN1198598C (enExample)
AR (1) AR030557A1 (enExample)
AT (1) ATE401867T1 (enExample)
AU (3) AU779623B2 (enExample)
BR (1) BRPI0110038C1 (enExample)
CA (1) CA2405508C (enExample)
CZ (1) CZ303943B6 (enExample)
DE (1) DE60134964D1 (enExample)
DK (1) DK1272167T3 (enExample)
ES (2) ES2580043T3 (enExample)
HU (1) HU228269B1 (enExample)
IL (2) IL152184A0 (enExample)
MX (1) MXPA02010151A (enExample)
NO (1) NO333572B1 (enExample)
NZ (1) NZ521902A (enExample)
PL (1) PL202689B1 (enExample)
PT (1) PT1272167E (enExample)
SI (1) SI1272167T1 (enExample)
WO (1) WO2001078688A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
ITMI20020514A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20070009596A1 (en) † 2003-05-14 2007-01-11 Bruschi Stefano D L Controlled drug release composition resistant to in vivo mechanic stress
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513147A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
JP2008520726A (ja) * 2004-11-19 2008-06-19 スミスクライン・ビーチャム・コーポレイション 医薬製品
EP1836665B1 (en) * 2004-11-19 2013-01-16 GlaxoSmithKline LLC Method for customized dispensing of variable dose drug combination products for individualizing of therapies
KR100905511B1 (ko) 2005-01-28 2009-07-01 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20100317763A1 (en) * 2005-11-09 2010-12-16 Jayanth Rajaiah Denture Adhesive Articles
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR100816064B1 (ko) * 2006-08-16 2008-03-24 주식회사 케이티앤지 홍삼이 함유된 다중 정제 및 이의 제조방법
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EP2063872B2 (en) 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20100136125A1 (en) * 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
KR101094231B1 (ko) * 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
JP5373069B2 (ja) * 2008-06-04 2013-12-18 ザ プロクター アンド ギャンブル カンパニー 義歯接着剤組成物及び方法
SI22849A (sl) * 2008-08-01 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Ropinirolni pripravek
WO2010015911A1 (en) * 2008-08-06 2010-02-11 Torrent Pharmaceuticals Limited Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof
WO2010023693A2 (en) * 2008-09-01 2010-03-04 Lupin Limited Novel controlled release compositions of ropinirole
CN102143739B (zh) * 2008-09-04 2014-12-17 百时美施贵宝公司 用于最优化传递hiv附着抑制剂的稳定的药用组合物
EP2163240A1 (en) 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
CA2738414C (en) 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
US7927264B2 (en) * 2009-07-24 2011-04-19 Fitness Iq Llc Low-impact inertial exercise device
WO2011032416A1 (zh) * 2009-09-19 2011-03-24 浙江华海药业股份有限公司 含有多巴胺受体激动剂的药物组合物
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
BR112012022646A2 (pt) 2010-03-10 2016-08-23 Procter & Gamble composições adesivas para dentaduras
CA2801332C (en) 2010-10-15 2016-08-23 Straumann Holding Ag New emd formulation comprising pga
GR1007629B (el) 2011-07-13 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
CA2937243C (en) * 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
US10485758B2 (en) 2014-06-02 2019-11-26 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
FR3026012B1 (fr) 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
ES2966736T3 (es) 2016-12-02 2024-04-24 Clexio Biosciences Ltd Sistema de residencia gástrica
JP7147262B2 (ja) * 2017-05-23 2022-10-05 大正製薬株式会社 固形製剤
WO2019111132A1 (en) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Long acting gastric residence system
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
JP7516738B2 (ja) * 2018-11-06 2024-07-17 大正製薬株式会社 多層錠
KR102536511B1 (ko) * 2020-06-25 2023-05-26 (주) 넥스팜코리아 날트렉손 서방형 매트릭스 제제와 부프로피온 서방형 매트릭스 제제의 단층정 복합제제와 그 제조 방법
JP7098008B2 (ja) * 2021-02-02 2022-07-08 ライオン株式会社 積層錠剤及びその製造方法
WO2025107056A1 (en) * 2023-11-23 2025-05-30 Sanofi Medley Farmaceutica Ltda Extended-release pharmaceutical composition and preparation process

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027748A (en) * 1997-01-08 2000-02-22 Jagotec Ag Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4452808A (en) 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4574082A (en) 1983-07-29 1986-03-04 Revlon, Inc. One-phase silicone-based cosmetic products containing wax
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
GB8714371D0 (en) 1987-06-19 1987-07-22 Smith Kline French Lab Process
US5032406A (en) 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
FI900871A7 (fi) 1989-02-24 1990-08-25 Gist Brocades Nv Pastöroinnin kestävä hapenpoistoaine
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JP2772695B2 (ja) 1990-01-26 1998-07-02 日水製薬株式会社 ３層錠
GB9008605D0 (en) 1990-04-17 1990-06-13 Smith Kline French Lab Process
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
GB9015095D0 (en) 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
JPH04360826A (ja) 1991-06-07 1992-12-14 Bayer Yakuhin Kk 放出制御製剤
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5186818A (en) 1991-08-12 1993-02-16 Exxon Research And Engineering Company Catalytic processes
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5308729A (en) * 1992-04-30 1994-05-03 Lexmark International, Inc. Electrophotographic liquid developer with charge director
JPH07506823A (ja) 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP0624373B1 (de) 1993-05-11 1999-09-08 Spirig Ag Pharmazeutische Präparate Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5387110A (en) 1993-11-12 1995-02-07 International Business Machines Corporation Reversible dual media adapter cable
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
KR100364328B1 (ko) * 1996-08-29 2002-12-26 사노피-신델라보 알푸조신 염산염의 제어방출 정제
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
WO1998030208A1 (en) * 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FR2766708B1 (fr) * 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
CN1209098C (zh) 1998-06-03 2005-07-06 阿尔扎有限公司 提供药物长效治疗的方法和装置
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
JP4360826B2 (ja) 2003-04-24 2009-11-11 シャープ株式会社 半導体膜およびその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027748A (en) * 1997-01-08 2000-02-22 Jagotec Ag Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption

Also Published As

Publication number Publication date
EP1272167B1 (en) 2008-07-23
PL202689B1 (pl) 2009-07-31
JP2009029813A (ja) 2009-02-12
KR100823392B1 (ko) 2008-04-17
EP3175848A1 (en) 2017-06-07
CZ303943B6 (cs) 2013-07-10
BRPI0110038B1 (pt) 2019-02-19
PT1272167E (pt) 2008-08-12
AU779623C (en) 2001-10-30
BR0110038A (pt) 2002-12-31
HU228269B1 (en) 2013-02-28
JP5420207B2 (ja) 2014-02-19
ES2307608T3 (es) 2008-12-01
CA2405508C (en) 2011-02-01
US8460706B2 (en) 2013-06-11
HK1053602A1 (en) 2003-10-31
NZ521902A (en) 2004-03-26
US20100003320A1 (en) 2010-01-07
US7927624B2 (en) 2011-04-19
HUP0300530A3 (en) 2006-07-28
NO20024919D0 (no) 2002-10-11
IL152184A (en) 2009-08-03
KR20030023859A (ko) 2003-03-20
AU4857601A (en) 2001-10-30
EP2343060A1 (en) 2011-07-13
AU779623B2 (en) 2005-02-03
NO333572B1 (no) 2013-07-08
KR20090094406A (ko) 2009-09-04
DK1272167T3 (da) 2008-09-08
ES2580043T3 (es) 2016-08-18
HUP0300530A2 (hu) 2003-09-29
WO2001078688A1 (en) 2001-10-25
CZ20023415A3 (cs) 2003-05-14
CN1198598C (zh) 2005-04-27
KR20080047630A (ko) 2008-05-29
CN1427717A (zh) 2003-07-02
IL152184A0 (en) 2003-05-29
AU2005201805B2 (en) 2009-07-23
AU2009230759A1 (en) 2009-11-19
CA2405508A1 (en) 2001-10-25
US20070264336A1 (en) 2007-11-15
US20030180359A1 (en) 2003-09-25
MXPA02010151A (es) 2003-09-10
SI1272167T1 (sl) 2008-12-31
JP5073907B2 (ja) 2012-11-14
KR20070065922A (ko) 2007-06-25
DE60134964D1 (de) 2008-09-04
EP1681051A1 (en) 2006-07-19
BRPI0110038B8 (pt) 2019-07-16
BRPI0110038C1 (pt) 2021-05-25
US8303986B2 (en) 2012-11-06
AU2005201805A1 (en) 2005-05-26
EP1681051B1 (en) 2016-04-06
NO20024919L (no) 2002-12-06
AR030557A1 (es) 2003-08-27
EP1272167A1 (en) 2003-01-08
PL365837A1 (en) 2005-01-10
JP2003530423A (ja) 2003-10-14
ATE401867T1 (de) 2008-08-15
US20110177167A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
KR100823392B1 (ko) 친수성/친유성 중합체 매트릭스 용량적 제제
JP2006160762A (ja) １種以上の薬剤を異なった放出速度で放出することのできる薬用錠剤
JPH09502738A (ja) 制御放出のための新規ビーズおよびそれらを含有する医薬製剤
EP2375903A1 (en) A method of treating insomnia
ZA200703810B (en) Dosage form time-lagged of drugs for the therapy of insomnia
EP1435921A1 (en) Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
ZA200209226B (en) Hydrophilic/lipophilic polymeric matrix dosage formulation.
HK1053602B (en) Ropinirole-containing hydrophilic/liphilic polymeric matrix dosage formulation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090821

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090908

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091124

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100920

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20091124

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20101224

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100920

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120313

Appeal identifier: 2010101009862

Request date: 20101224

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20120316

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20120313

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150527

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150527

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160531

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160531

Start annual number: 5

End annual number: 5

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20170125

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20120615

Comment text: Registration of Establishment

Request date: 20170125

Appeal identifier: 2017100000238

Appeal kind category: Confirmation of the scope of right_defensive

FPAY Annual fee payment

Payment date: 20170525

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170525

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180518

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180518

Start annual number: 7

End annual number: 7

J301 Trial decision

Free format text: TRIAL NUMBER: 2017100000238; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170125

Effective date: 20190522

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20190522

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20170125

Decision date: 20190522

Appeal identifier: 2017100000238

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190530

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200526

Start annual number: 9

End annual number: 9

PC1801 Expiration of term

Termination date: 20211012

Termination category: Expiration of duration